Inivata Appoints Chair
This article was originally published in Scrip
Inivata Ltd., a cancer genomics company, has appointed Jeffrey Buchalter non-executive director and chair of its board. Most recently, Buchalter was CEO of Archimedes Pharma Ltd. and also received an award from the American Cancer Society for his commitment to cancer control and involvement in the oncology field. Buchalter has also been collaborating partner in the President's National Dialogue on Cancer and acted as chair of the board at National Childhood Cancer Foundation in the US.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.